PRESS RELEASE published on 12/06/2023 at 12:30, 11 months 15 days ago Zomedica Announces Presentation of Clinical Data in Support of New Indications for PulseVet Shock Wave Therapy at Annual Meeting of American Association of Equine Practitioners Zomedica announces presentation of clinical data in support of new indications for Pulsevet shock wave therapy at annual meeting of American Association of Equine Practitioners Zomedica Pulsevet Shock Wave Therapy Veterinary Health Clinical Data
PRESS RELEASE published on 11/28/2023 at 12:30, 11 months 23 days ago Zomedica to Present at Noble Capital Markets' 19th Annual Emerging Growth Equity Conference
PRESS RELEASE published on 11/20/2023 at 12:30, 1 year ago Zomedica to Present at the 35th Annual Piper Sandler Healthcare Conference
PRESS RELEASE published on 11/13/2023 at 22:20, 1 year ago Zomedica Announces Record Third Quarter 2023 Financial Results: Revenue up 31% to $6.3 Million; 69% Gross Margin, and $118 Million in Liquidity, while Making Strategic Acquisitions of Structured Monitoring Products and Qorvo Biotechnologies
PRESS RELEASE published on 11/02/2023 at 11:30, 1 year ago Zomedica to Report Third Quarter 2023 Financial Results and Provide Business Update on November 13 at 4:30 p.m. ET
PRESS RELEASE published on 10/10/2023 at 06:00, 1 year 1 month ago Zomedica to Participate in the Lytham Partners Fall 2023 Investor Conference
PRESS RELEASE published on 10/05/2023 at 12:30, 1 year 1 month ago Zomedica Announces Acquisition of TRUFORMA Platform Developer Qorvo Biotech LLC, Accelerating Timeline to Gain Control of Manufacturing and Research & Development
PRESS RELEASE published on 09/14/2023 at 12:30, 1 year 2 months ago Zomedica Announces Expansion of Market Opportunity for TRUFORMA(R) Diagnostic Platform with Launch of First-and-only Point of Care eACTH Assay for Diagnosis and Management of Cushing’s Disease in Horses
PRESS RELEASE published on 09/13/2023 at 22:30, 1 year 2 months ago Zomedica Provides Corporate Update
PRESS RELEASE published on 09/05/2023 at 22:30, 1 year 2 months ago Zomedica Closes Acquisition of Structured Monitoring Products Adding Revolutionary VetGuardian Touchless Vital Signs Monitor to Product Portfolio
Published on 11/21/2024 at 22:05, 1 hour 30 minutes ago Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Published on 11/21/2024 at 21:50, 1 hour 45 minutes ago Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Published on 11/21/2024 at 20:15, 3 hours 20 minutes ago Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals
Published on 11/21/2024 at 20:10, 3 hours 25 minutes ago For Us TV Productions, a Portfolio Company of Belle Bonica Luxe Corp., Invites BIPOC Filmmakers and Producers to Join Its Inclusive Streaming Platform
Published on 11/21/2024 at 20:00, 3 hours 35 minutes ago Victory for New York Homeowners: Petroff Amshen LLP Blocks Lender’s Repeated Foreclosure Attempt
Published on 11/21/2024 at 19:01, 4 hours 34 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/21/2024 at 18:36, 4 hours 59 minutes ago Original-Research: Beaconsmind AG (von First Berlin Equity Research GmbH): BUY
Published on 11/21/2024 at 17:58, 5 hours 37 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/21/2024 at 17:51, 5 hours 44 minutes ago LIGHTON announces highly successful IPO on Euronext Growth Paris.
Published on 11/21/2024 at 17:51, 5 hours 44 minutes ago 2CRSi SA: 2CRSi supplies Exaion, a subsidiary of the EDF Group, with high-performance immersion servers in North America.
Published on 11/21/2024 at 06:58, 16 hours 37 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 1 day 4 hours ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 1 day 5 hours ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 1 day 5 hours ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 15 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
